BOTOX® is a Prescription Medicine containing 100 units of botulinum toxin type A for injection. It is used for the treatment of frown lines, forehead lines and crow’s feet. Dysport® is a Prescription Medicine containing 500 units of Clostridium botulinumin toxin type A for injection. It is used for the treatment of Glabellar lines. They should be administered only by trained medical professionals. Ask your specialist about the benefits and risks of using Botox or Dysport and whether they are right for you. If you have any side effects or concerns speak to your health professional. You will need to pay for Botox and Dysport. They have benefits and risks. Always follow your specialist’s instructions. For more information refer to the Consumer Medicine Information for Botox or Dysport at www.medsafe.govt.nz
BOTOX® is a registered trademark of Allergan, Inc. Allergan New Zealand Ltd, PO Box 1873, Shortland Street, Auckland 1140, New Zealand.
Dysport is distributed by Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics
P O Box 62027, Sylvia Park, Auckland 1644
BELKYRA® injection is a prescription medicine containing 10 mg/mL deoxycholic acid. It is used for the improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. Do not use in people allergic to this medicine, with infection at site of injection, pregnancy and lactation. Possible side effects include headaches, difficulty swallowing, nausea, skin tightness, hypertension, injection site bruising/pain/swelling/numbness/redness/tingling/hardness/itching/discolouration/formation of small areas of hardness/warmth and injection site nerve injury. BELKYRA® treatment is not funded on the New Zealand Pharmaceutical Schedule. You will need to pay for this medicine. Normal Doctors visit fees apply. BELKYRA® treatment should be administered only by trained medical professionals. Speak to your specialist about your own situation and about the benefits/risks of this procedure in appearance medicine. For further information, the Data Sheet and Consumer Medicines Information can be accessed at www.medsafe.govt.nz or ask your doctor. If you have any side effects or concerns speak to your doctor. Note: Results from BELKYRA® treatment usually last up to four years.
BELKYRA® and its design are trademarks of Kythera Biopharmaceuticals, Inc., an Allergan affiliate. ™Trademark of Allergan, Inc. Allergan Australia Pty Ltd, 810 Pacific Highway, Gordon NSW 2072. ABN 85 000 612 831. Allergan New Zealand Limited, Auckland. © 2018 Allergan. All rights reserved. Date of preparation: January 2018.